Halsa Pharmaceuticals Announces Promising Results for Zinc-2-glycoprotein (ZAG) Treatment for Obesity and Type 2 Diabetes

Strategic Insights -

Halsa Pharmaceuticals, a biotechnology company, has announced results from preclinical studies demonstrating the potential of recombinant human Zinc-2-glycoprotein (ZAG) in treating obesity and Type 2 diabetes. The studies showed that ZAG induced a progressive loss of body weight in mice, along with an increase in temperature and metabolic hallmarks of Type 2 diabetes. These results were presented at the 27th Annual Scientific Meeting of The Obesity Society in Washington, D.C.

Key Takeaways:

  • ZAG induced a progressive loss of body weight in mice of 3.5g in five days, with a rise in temperature of 0.4°C, suggesting an increase in energy expenditure.
  • ZAG produced a normalization of the diabetic glucose tolerance curve after three days of treatment, indicating its therapeutic potential in treating obesity and Type 2 diabetes.
  • The compound decreased blood glucose and plasma insulin levels, while increasing pancreatic insulin levels and glucose uptake into adipose tissue and skeletal muscle.
  • ZAG administration increased skeletal muscle mass due to an increase in protein synthesis and a decrease in protein degradation.
  • The compound demonstrates a low expectation of acute toxicity due to its medium prevalence in the human body.

Statistics:

  • 3.5g weight loss in mice over five days
  • 0.4°C rise in temperature
  • 4-fold increase in pancreatic insulin levels
  • 3-day normalization of diabetic glucose tolerance curve
  • 50% increase in glucose uptake into adipose tissue and skeletal muscle
  • 2.5% increase in skeletal muscle mass

Sources:

  • Halsa Pharmaceuticals, Inc. press release, dated October 24, 2009.
  • Professor Michael J. Tisdale, Aston University, Birmingham, U.K.
  • Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, Washington, D.C., October 24-28.